A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage ...

BUFFALO, N.Y. — One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 are targeted covalent inhibitors (TCIs). These small molecule drugs form covalent ...

Two posters presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exhibition focused on overall survival associated with real-world treatment sequences in patients with chronic ...

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the initial promise it saw with its BTK inhibitor Jaypirca (pirtobrutinib). Just ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...